NTNadia Tavakolidakhrabadi

Nadia Tavakolidakhrabadi

*This is an algorithmically generated author record based on publicly available information.

Nadia Tavakolidakhrabadi has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Carl May

    Bristol Renal, University of Bristol, Dorothy Hodgkin Building, Whitson Street, Bristol BS1 3NY, UK

    1 shared publication
  • Gavin I Welsh

    Bristol Medical School, Bristol Renal, University of Bristol , Dorothy Hodgkin Building, Whitson Street, Bristol

    1 shared publication
  • Gavin I. Welsh

    Bristol Renal, University of Bristol, Dorothy Hodgkin Building, Whitson Street, Bristol BS1 3NY, UK

    1 shared publication
  • Moin A. Saleem

    Bristol Renal, University of Bristol, Dorothy Hodgkin Building, Whitson Street, Bristol BS1 3NY, UK

    1 shared publication
  • Moin A. Saleem

    Bristol Renal, University of Bristol and Bristol Royal Hospital for Children, Bristol, UK

    1 shared publication
  • Wen Y. Ding

    Bristol Renal, University of Bristol, Dorothy Hodgkin Building, Whitson Street, Bristol BS1 3NY, UK

    1 shared publication

Latest Publications

  • Open Access

    Molecular mechanisms in podocytopathies: finding suitable targets for a new era of glomerular gene therapy

    by Nadia Tavakolidakhrabadi, Wen Y Ding, Gavin I Welsh, Moin A Saleem

    Podocytopathies encompass a spectrum of glomerular disorders driven by structural and functional impairments in podocytes: specialized cells critical for maintaining the glomerular filtration barrier. Dysregulation of key podocyte components—such as slit-diaphragm proteins (nephrin, podocin), cytoskeletal regulators (ACTN4, TRPC6), and adhesion complexes (integrins, dystroglycan)—leads to proteinuria and progressive glomerulosclerosis. Current therapies often fail to address underlying genetic or molecular defects, particularly in hereditary or refractory cases. Gene therapy has emerged as a transformative approach, leveraging adeno-associated viral (AAV) vectors, CRISPR-based editing, and RNA modulation to correct pathogenic mutations or restore disrupted pathways. Recent advances in capsid engineering, tissue-specific promoters, and delivery strategies have enhanced podocyte targeting while minimizing off-target effects. Preclinical successes, including AAV-mediated rescue of NPHS2-associated nephrotic syndrome and complement modulation in IgA nephropathy, highlight the therapeutic potential. However, challenges such as immune responses, vector biodistribution, and disease heterogeneity remain. This review synthesizes the molecular mechanisms underlying podocytopathies, evaluates current gene-therapy strategies, and discusses translational hurdles and future directions, including patient-derived organoid models and combinatorial therapies. By bridging mechanistic insights with innovative gene-based interventions, this work underscores the promise of precision medicine in revolutionizing the treatment of podocytopathies.


  • Open Access

    Gene therapy and kidney diseases

    by Nadia Tavakolidakhrabadi, Wen Y. Ding, Moin A. Saleem, Gavin I. Welsh, Carl May